Blog Posts

Stephen Liu: Interesting look at immediate versus deferred systemic therapy in patients with pleural mesothelioma at Clinical Lung Cancer

Photo from Stephen Liu/X

Apr 28, 2024, 10:18

Stephen Liu: Interesting look at immediate versus deferred systemic therapy in patients with pleural mesothelioma at Clinical Lung Cancer

Stephen Liu, Director of Thoracic Oncology and Developmental Therapeutics at Georgetown University, shared on X/Twitter:

“Certainly confounders here, but interesting look at immediate versus deferred systemic therapy in patients with pleural mesothelioma at Clinical Lung Cancer. In this group, 58% of deferred patients eventually had systemic therapy. OS longer in deferred group (20.6m vs 11.5m).”

Visit the article website.
Source: Stephen Liu/X

cancer Clinical Lung Cancer immediate systemic therapy Lung cancer OncoDaily Oncology overall survival pleural mesothelioma Stephen Liu systemic therapy

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC